Audit and screening study to determine the prevalence of peripheral arterial disease - ACHILLES
Study identifier:D3560L00089
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Audit and screening study to determine the prevalence of peripheral arterial disease. A cross-sectional multi-centre clinical study in subjects with cardiovascular disease risk factors.
Medical condition
Peripheral Arterial Disease
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
1000
Study type
Interventional
Age
45 Years +
Date
Study Start Date: 01 Jun 2009
Primary Completion Date: -
Study Completion Date: 01 Oct 2009
Study design
Allocation: N/A
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Pretium Pty Ltd
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: All Subjects ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease. | Procedure/Surgery: Ankle-brachial index (ABI) Screening Test Patients will undergo an ABI measurement |
Contacts
Investigators
Principal Investigator
Simon Fisher
AstraZeneca
